Development Of Unconventional Response And Related Efficacy Evaluation Of ICIs In The Treatment Of Solid Tumors

With the development of immunology and molecular biology,immunotherapy has become a novel mode of anti-tumor therapy.In particular,immunocheckpoint inhibitors,regarded as one of the most promising therapies,have been widely applied to the clinical practice and shown excellent prospects in the treatment of solid tumors.But a growing body of evidence suggests that immunotherapies bring about abnormal response models different from those of tradition’s,including pseudoprogress,delayed reaction,and so on.At the same time,study confirms that the traditional response evaluation criteria in solid tumors often cannot accurately capture such abnormal reactions,which is difficult to estimate the immune treatment curative effect,which brought great trouble for clinical work and challenges.Therefore,new criteria for evaluating the efficacy of immunotherapy for solid tumors need to be developed and improved urgently,leading to a series of immune-related evaluation criteria proposed.In this article,the development and application of the unconventional response patterns and related efficacy evaluation criteria of solid tumor immunotherapy,mainly checkpoint inhibitor therapy,are reviewed.